Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR7 | P34969 | 5/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9688702 | 0.86 | MAPT (0.41) | ACHEDRD2SLC6A4HTR3A | |
| SCHEMBL7539608 | 0.83 | DRD2 (0.47) | DRD2HTR2AHTR7HTR6 | |
| SCHEMBL24410388 | 0.82 | DRD2 (0.47) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL19141702 | 0.82 | ACHE (0.42) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL3523748 | 0.80 | ACHE (0.45) | ACHE | |
| SCHEMBL5450472 | 0.79 | DRD2 (0.43) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL9688281 | 0.79 | ALDH1A1 (0.42) | ACHECHRNA7HTR3A | |
| SCHEMBL4406390 | 0.79 | MAPT (0.46) | CHRNA7HTR3A | |
| SCHEMBL7093631 | 0.78 | ACHE (0.39) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL19142287 | 0.78 | MAPT (0.39) | ACHEDRD2SLC6A4HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574945-B | Isoxazoline derivatives and their use in agriculture | 东莞市东阳光农药研发有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3192792-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Vigonvita Life Sciences Co., Ltd. (CN) | 2017-07-19 | — | — | EP | disclosed |
| US-8501750-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PCSK9, APOB, REN | ACHE 166/4885DRD2 1346/4885SLC6A4 544/4885 |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | NOTUM, ALDH7A1, HADHB | ACHE 1454/4885DRD2 4432/4885SLC6A4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.